Longleaf Partners Fund Releases Fourth Quarter 2025 Investor Letter
Longleaf Partners Fund reported a 3.35% return for Q4 2025, underperforming some benchmarks. The letter detailed its position in Regeneron Pharmaceuticals, noting the company's financial actions and pipeline.